Front Row Advisors LLC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.2%.

Quarter-by-quarter ownership
Front Row Advisors LLC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$6,095
+86971.4%
117
+8.3%
0.00%0.0%
Q2 2023$7
+16.7%
1080.0%0.00%0.0%
Q1 2023$6
+50.0%
108
+27.1%
0.00%
+50.0%
Q4 2022$4
-99.9%
850.0%0.00%0.0%
Q3 2022$4,000850.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2022
NameSharesValueWeighting ↓
Sarissa Capital Management LP 675,000$26,203,0007.44%
EcoR1 Capital, LLC 244,950$9,509,0003.75%
Redmile Group, LLC 971,565$37,716,0003.60%
Ghost Tree Capital, LLC 120,000$4,658,0001.34%
SENZAR ASSET MANAGEMENT, LLC 144,624$5,614,304,0001.22%
GREAT POINT PARTNERS LLC 100,000$3,882,0001.11%
BB BIOTECH AG 700,000$27,174,0001.07%
Rhenman & Partners Asset Management AB 115,000$4,464,0000.79%
Lisanti Capital Growth, LLC 12,260$476,0000.72%
Rock Springs Capital Management LP 190,000$7,376,0000.55%
View complete list of INTRA CELLULAR THERAPIES INC shareholders